{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:05Z","timestamp":1787755865808,"version":"build-2784847793"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,12,7]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Combination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab (an anti-programmed cell death protein-1 antibody) in combination with famitinib (a receptor tyrosine kinase inhibitor) for the treatment of platinum-resistant ROC from an open-label, multicenter, phase 2 basket trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients with platinum-resistant ROC were enrolled to receive camrelizumab (200\u2009mg every 3 weeks by intravenous infusion) and oral famitinib (20\u2009mg once daily). All patients had disease progression during or &lt;6 months after their most recent platinum-based chemotherapy. Primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 based on investigator\u2019s assessment. Secondary endpoints included disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 37\u2009women enrolled, 11 (29.7%) patients had primary platinum resistant, 15 (40.5%) patients had secondary platinum resistant and 11 (29.7%) patients had primary platinum refractory disease. As the cut-off date of April 9, 2021, nine (24.3%) patients had achieved a confirmed objective response, the ORR was 24.3% (95% CI, 11.8 to 41.2) and the DCR was 54.1% (95% CI, 36.9 to 70.5). Patients with this combination regimen showed a median TTR of 2.1 months (range, 1.8\u20134.1) and a median DoR of 4.1 months (95%\u2009CI, 1.9 to 6.3). Median PFS was 4.1 months (95%\u2009CI, 2.1 to 5.7), and median OS was 18.9 months (95%\u2009CI, 10.8 to not reached), with the median follow-up duration of 22.0 months (range, 12.0\u201323.7). The estimated 12-month OS rate was 67.2% (95% CI, 49.4 to 79.9). The most common \u2265grade 3 treatment-related adverse events were hypertension (32.4%), decreased neutrophil count (29.7%) and decreased platelet count (13.5%). One (2.7%) patient died of grade 5 hemorrhage that was judged possibly related to study treatment by investigator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The camrelizumab with famitinib combination appeared to show antitumor activity in heavily pretreated patients with platinum-resistant ROC with an acceptable safety profile. This combination might provide a novel alternative treatment strategy in platinum-resistant ROC setting and warranted further exploration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03827837\">NCT03827837<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003831","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T11:35:35Z","timestamp":1641900935000},"page":"e003831","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03827837","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lingfang","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Affiliated Tumor Hospital of Chongqing University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nanjing Drum Tower Hospital, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-7397","authenticated-orcid":false,"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Xiangya Hospital Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanren","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"2025100312042843000_10.1.e003831.1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24149"},{"key":"2025100312042843000_10.1.e003831.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071663","article-title":"Immune-Checkpoint inhibitors in platinum-resistant ovarian cancer","volume":"13","author":"Indini","year":"2021","journal-title":"Cancers"},{"key":"2025100312042843000_10.1.e003831.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"2025100312042843000_10.1.e003831.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"2025100312042843000_10.1.e003831.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.09.039"},{"key":"2025100312042843000_10.1.e003831.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611533104"},{"key":"2025100312042843000_10.1.e003831.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"2025100312042843000_10.1.e003831.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.017"},{"key":"2025100312042843000_10.1.e003831.9","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100312042843000_10.1.e003831.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00867","article-title":"Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing epithelial-mesenchymal transition","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"2025100312042843000_10.1.e003831.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543"},{"key":"2025100312042843000_10.1.e003831.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102224","article-title":"Recent advancements of antiangiogenic combination therapies in ovarian cancer","volume":"98","author":"An","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025100312042843000_10.1.e003831.13","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100312042843000_10.1.e003831.14","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"2025100312042843000_10.1.e003831.15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100312042843000_10.1.e003831.16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00280-013-2282-y","article-title":"Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib","volume":"72","author":"Zhou","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025100312042843000_10.1.e003831.17","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12047"},{"key":"2025100312042843000_10.1.e003831.18","doi-asserted-by":"crossref","first-page":"5838-5846","DOI":"10.1158\/1078-0432.CCR-21-1698","article-title":"Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase II basket study","volume":"27","author":"Qu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025100312042843000_10.1.e003831.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.979","article-title":"840P famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian\/fallopian tube\/primary peritoneal cancer and advanced cervical cancer: an open-label, multicenter phase II study","volume":"31","author":"Xia","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100312042843000_10.1.e003831.20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5085","article-title":"Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: a multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Y-Y","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100312042843000_10.1.e003831.21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4550","article-title":"Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: updated results from a phase II trial","volume":"39","author":"Y-Y","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100312042843000_10.1.e003831.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2004.00193.x"},{"key":"2025100312042843000_10.1.e003831.23","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and clinical activity of the programmed Death-Ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers: a dose-escalation, phase I study","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100312042843000_10.1.e003831.24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100312042843000_10.1.e003831.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397"},{"key":"2025100312042843000_10.1.e003831.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"2025100312042843000_10.1.e003831.27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100312042843000_10.1.e003831.28","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100312042843000_10.1.e003831.29","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100312042843000_10.1.e003831.30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025100312042843000_10.1.e003831.31","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0263-y"},{"key":"2025100312042843000_10.1.e003831.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"2025100312042843000_10.1.e003831.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"2025100312042843000_10.1.e003831.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3136"},{"key":"2025100312042843000_10.1.e003831.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"2025100312042843000_10.1.e003831.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4691"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:04:37Z","timestamp":1759518277000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,11]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003831"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003831","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}